Gilead Sciences stock jumps on HIV treatment trial success Yahoo FinanceGilead’s twice-yearly shot to prevent HIV succeeds in late-stage trial CNBCGilead’s Twice-Yearly Shot Prevents HIV. Where the Stock Is Headed. Barron’sWatch out, GSK. Gilead’s twice-yearly PrEP drug shows 100% efficacy for HIV prevention FiercePharmaGilead says its HIV prevention shot was 100% effective in a clinical trial Quartz